PRT1419 + venetoclax

PRT1419 + venetoclax is a combination of two small molecules being studied primarily for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), MDS/myeloproliferative overlap, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and B-cell non-Hodgkin lymphoma. - **PRT1419** is a potent, selective, and orally bioavailable inhibitor of the anti-apoptotic protein myeloid cell leukemia-1 (MCL-1), promoting apoptosis in cancer cells dependent on MCL-1 for survival. - **Venetoclax** is an inhibitor of B-cell lymphoma-2 (BCL-2), another anti-apoptotic protein, and is approved for several hematologic malignancies. The rationale of this combination is that inhibition of both MCL-1 and BCL-2 can overcome resistance to single-agent therapy and induce synergistic apoptotic cell death in cancer cells. This regimen is currently under investigation in Phase 1 clinical trials focused on establishing safety and efficacy in various malignancies[1][2][6][7].

Other names

PRT1419 + VENPRT1419 and venetoclaxPRT-1419 and venetoclaxPRT 1419 and venetoclax